Novartis
Real-World Studies Aim to Optimize Treatment Sequence for Novartis' Pluvicto in Prostate Cancer
Premium
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.
UK's MHRA Approves Kisqali, Aromatase Inhibitor in Early-Stage Breast Cancer
The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.
Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
JP Morgan Healthcare Conference, Day 2: Novartis, Relay, Erasca, Syndax, AstraZeneca, and More
On the second day, Novartis boasted of Kisqali's $8 billion potential, Relay said it's taking a PI3Kα inhibitor into Phase III, and Syndax talked about Revuforj in NPM1-mutant AML.